Literature DB >> 26798590

Alectinib in RET-rearranged non-small cell lung cancer-Another progress in precision medicine?

Robert Pirker1, Martin Filipits1.   

Abstract

RET fusions have been recognized as potential therapeutic targets in advanced non-small cell lung cancer. RET fusion proteins are detected in about 2% of lung adenocarcinomas. Alectinib, a second generation ALK inhibitor, was shown to block growth of cells with RET fusions. Thus alectinib should be further evaluated within clinical trials in patients with RET fusion-positive adenocarcinomas of the lung.

Entities:  

Keywords:  Alectinib; RET; biomarker; targeted therapy; tyrosine kinase inhibitor

Year:  2015        PMID： 26798590      PMCID： PMC4700226          DOI： 10.3978/j.issn.2218-6751.2015.03.08

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


  21 in total

1.  Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

Authors:  Shirish M Gadgeel; Leena Gandhi; Gregory J Riely; Alberto A Chiappori; Howard L West; Michele C Azada; Peter N Morcos; Ruey-Min Lee; Linta Garcia; Li Yu; Frederic Boisserie; Laura Di Laurenzio; Sophie Golding; Jotaro Sato; Shumpei Yokoyama; Tomohiro Tanaka; Sai-Hong Ignatius Ou
Journal:  Lancet Oncol       Date:  2014-08-18       Impact factor: 41.316

2.  Activation of a novel human transforming gene, ret, by DNA rearrangement.

Authors:  M Takahashi; J Ritz; G M Cooper
Journal:  Cell       Date:  1985-09       Impact factor: 41.582

Review 3.  Epidermal growth factor receptor-directed monoclonal antibodies in nonsmall cell lung cancer: an update.

Authors:  Robert Pirker
Journal:  Curr Opin Oncol       Date:  2015-03       Impact factor: 3.645

4.  CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.

Authors:  Hiroshi Sakamoto; Toshiyuki Tsukaguchi; Sayuri Hiroshima; Tatsushi Kodama; Takamitsu Kobayashi; Takaaki A Fukami; Nobuhiro Oikawa; Takuo Tsukuda; Nobuya Ishii; Yuko Aoki
Journal:  Cancer Cell       Date:  2011-05-17       Impact factor: 31.743

5.  Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.

Authors:  Tatsushi Kodama; Toshiyuki Tsukaguchi; Yasuko Satoh; Miyuki Yoshida; Yoshiaki Watanabe; Osamu Kondoh; Hiroshi Sakamoto
Journal:  Mol Cancer Ther       Date:  2014-10-27       Impact factor: 6.261

6.  GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF.

Authors:  S Jing; D Wen; Y Yu; P L Holst; Y Luo; M Fang; R Tamir; L Antonio; Z Hu; R Cupples; J C Louis; S Hu; B W Altrock; G M Fox
Journal:  Cell       Date:  1996-06-28       Impact factor: 41.582

7.  Targeted therapies in lung cancer.

Authors:  Robert Pirker; Martin Filipits
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

8.  Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.

Authors:  Alexander Drilon; Lu Wang; Adnan Hasanovic; Yoshiyuki Suehara; Doron Lipson; Phil Stephens; Jeffrey Ross; Vincent Miller; Michelle Ginsberg; Maureen F Zakowski; Mark G Kris; Marc Ladanyi; Naiyer Rizvi
Journal:  Cancer Discov       Date:  2013-03-26       Impact factor: 39.397

9.  RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.

Authors:  Rui Wang; Haichuan Hu; Yunjian Pan; Yuan Li; Ting Ye; Chenguang Li; Xiaoyang Luo; Lei Wang; Hang Li; Yang Zhang; Fei Li; Yongming Lu; Qiong Lu; Jie Xu; David Garfield; Lei Shen; Hongbin Ji; William Pao; Yihua Sun; Haiquan Chen
Journal:  J Clin Oncol       Date:  2012-11-13       Impact factor: 44.544

10.  RET, ROS1 and ALK fusions in lung cancer.

Authors:  Kengo Takeuchi; Manabu Soda; Yuki Togashi; Ritsuro Suzuki; Seiji Sakata; Satoko Hatano; Reimi Asaka; Wakako Hamanaka; Hironori Ninomiya; Hirofumi Uehara; Young Lim Choi; Yukitoshi Satoh; Sakae Okumura; Ken Nakagawa; Hiroyuki Mano; Yuichi Ishikawa
Journal:  Nat Med       Date:  2012-02-12       Impact factor: 53.440
View more
  2 in total

Review 1.  Targeted Lung Cancer Treatments and Eye Metastasis.

Authors:  Paul Zarogoulidis; Sofia Baka; Sofia Labaki; George Lazaridis; Georgia Trakada
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2017

2.  Non-secretory multiple myeloma with unusual TFG-ALK fusion showed dramatic response to ALK inhibition.

Authors:  Ashiq Masood; Trevor Christ; Samia Asif; Priya Rajakumar; Beth A Gustafson; Leyla O Shune; Ameen Salahudeen; Drew Nedvad; Suparna Nanua; Agne Paner; Timothy M Kuzel; Mia Levy; Janakiraman Subramanian; Shahzad Raza
Journal:  NPJ Genom Med       Date:  2021-03-17       Impact factor: 8.617
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.